Cargando…

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells

PURPOSE: Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class inhibitor for the treatment of r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Yundeok, Jeung, Hoi-Kyung, Cheong, June-Won, Song, Jaewoo, Bae, Soo Han, Lee, Jong In, Min, Yoo Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471081/ https://www.ncbi.nlm.nih.gov/pubmed/32882760 http://dx.doi.org/10.3349/ymj.2020.61.9.762

Ejemplares similares

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance
por: CHEONG, JUNE-WON, et al.
Publicado: (2016)

Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells
por: Kim, Soo-Jeong, et al.
Publicado: (2012)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
por: Boutzen, Héléna, et al.
Publicado: (2016)

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1
por: Paubelle, Etienne, et al.
Publicado: (2019)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Pharmacokinetics of All‐trans Retinoic Acid in Pediatric Patients with Leukemia
por: Takitani, Kimitaka, et al.
Publicado: (1995)

All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage
por: Xu, Zhifei, et al.
Publicado: (2016)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

Sweet’s syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid
por: Park, Chi Jun, et al.
Publicado: (2001)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment
por: Su, Meng, et al.
Publicado: (2015)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
por: Fredly, Hanne, et al.
Publicado: (2013)

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
por: Nazha, Aziz, et al.
Publicado: (2013)

All-Trans Retinoic Acid Enhances Matrix Metalloproteinase 2 Expression and Secretion in Human Myeloid Leukemia THP-1 Cells
por: Vu, Hien Thi, et al.
Publicado: (2018)

All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells
por: Nguyen, Chi H., et al.
Publicado: (2020)

All-Trans-Retinoic Acid Combined With Valproic Acid Can Promote Differentiation in Myeloid Leukemia Cells by an Autophagy Dependent Mechanism
por: Benjamin, Dalyia N., et al.
Publicado: (2022)

All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis
por: Ma, Yafang, et al.
Publicado: (2016)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

All-trans-retinoic acid–induced pseudotumor cerebri in acute promyelocytic leukemia
por: Anoop, T. M., et al.
Publicado: (2014)

The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid
por: Steinmetz, Birgit, et al.
Publicado: (2014)

Targeting of myeloid-derived suppressor cells by all-trans retinoic acid as host-directed therapy for human tuberculosis
por: Leukes, Vinzeigh N., et al.
Publicado: (2021)

All Trans Retinoic Acid, Transforming Growth Factor β and Prostaglandin E(2) in Mouse Plasma Synergize with Basophil-Secreted Interleukin-4 to M2 Polarize Murine Macrophages
por: Ho, Victor W., et al.
Publicado: (2016)

Transdifferentiation of Myoblasts Into Adipocytes by All-Trans-Retinoic Acid in Avian
por: Kim, Dong-Hwan, et al.
Publicado: (2022)

Potential Therapeutic Effect of All-Trans Retinoic Acid on Atherosclerosis
por: Deng, Qile, et al.
Publicado: (2022)

Deregulation of All-Trans Retinoic Acid Signaling and Development in Cancer
por: Brown, Geoffrey
Publicado: (2023)

All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia
por: Yoshida, Tetsumi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7rmd1ov9qp4oc91uedthcnr23b